Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease
Status:
Completed
Trial end date:
2004-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die.
PURPOSE: Phase II trial to study the effectiveness of bryostatin 1 in treating patients who
have recurrent or refractory Hodgkin's disease.